Publications by authors named "Yi-Min Zheng"
Article Synopsis
- SARS-CoV-2 is evolving, resulting in new variants like XEC, which has specific mutations (T22N and F59S) in the spike protein that affect how the virus interacts with neutralizing antibodies.
- The study analyzed immune responses from different vaccinated groups and found that XEC had significantly lower neutralization levels due to the F59S mutation, but removing certain glycosylation sites could restore these levels.
- The research highlights that mutations in the N-terminal domain of the spike protein play a crucial role in the virus's ability to evade the immune system and change its structural properties.
Article Synopsis
- In the summer of 2024, a global increase in COVID-19 cases was attributed to JN.1 subvariants of SARS-CoV-2, which have new mutations, particularly in the spike protein's N-terminal domain (NTD).
- The study found that several subvariants (LB.1, KP.2.3, KP.3, and KP.3.1.1) largely escape neutralizing antibodies from various vaccines and past infections due to a key deletion (DelS31) in the spike protein.
- The DelS31 mutation enhances the stability of the spike protein and introduces changes that help the virus avoid immune detection, suggesting a possible need to update COVID-19 vaccines to include antigens
Article Synopsis
- This study examines how subvariants of JN.1 (SLip, FLiRT, and KP.2) respond to neutralization by antibodies from vaccinated people and infected patients, discovering they show increased resistance compared to the original JN.1.
- The research finds that while hamster sera from XBB.1.5 vaccinations can strongly neutralize FLiRT and KP.2, SLip has reduced neutralization effectiveness. All subvariants demonstrate resistance to the antibody S309 and show decreased infectivity and other functionalities compared to JN.1.
- Key mutations in the spike protein of these subvariants are identified, affecting their interaction with antibodies and suggesting that new vaccines might need to
Lenvatinib is the most common multitarget receptor tyrosine kinase inhibitor for the treatment of advanced hepatocellular carcinoma (HCC). Acquired resistance to lenvatinib is one of the major factors leading to the failure of HCC treatment, but the underlying mechanism has not been fully characterized. We established lenvatinib-resistant cell lines, cell-derived xenografts (CDXs) and patient-derived xenografts (PDXs) and obtained lenvatinib-resistant HCC tumor tissues for further study.
View Article and Find Full Text PDFArticle Synopsis
- SARS-CoV-2 variants like JN.1 and its subvariants SLip, FLiRT, and KP.2 show increased resistance to neutralization by antibodies in previously vaccinated individuals and those who recovered from COVID-19 during the BA.2.86/JN.1 wave.
- While XBB.1.5 monovalent vaccinated hamsters have effectively neutralized FLiRT and KP.2, SLip demonstrated reduced efficiency in antibody response.
- Key mutations in the spike protein of these subvariants affect their infectivity and resistance to neutralization, highlighting the need for future vaccines to consider adaptations involving the JN.1 spike protein.
Unlabelled: The rapid evolution of SARS-CoV-2 variants presents a constant challenge to the global vaccination effort. In this study, we conducted a comprehensive investigation into two newly emerged variants, BA.2.
View Article and Find Full Text PDFThe rapid evolution of SARS-CoV-2 variants presents a constant challenge to the global vaccination effort. In this study, we conducted a comprehensive investigation into two newly emerged variants, BA.2.
View Article and Find Full Text PDFThe evolution of SARS-CoV-2 paired with immune imprinting by prototype messenger RNA (mRNA) vaccine has challenged the current vaccination efficacy against newly emerged Omicron subvariants. In our study, we investigated a cohort of macaques infected by SIV and vaccinated with two doses of bivalent Pfizer mRNA vaccine containing wildtype and BA.5 spikes.
View Article and Find Full Text PDFCombination therapy (lenvatinib/programmed death-1 inhibitor) is effective for treating unresectable hepatocellular carcinoma (uHCC). We reveal that responders have better overall and progression-free survival, as well as high tumor mutation burden and special somatic variants. We analyze the proteome and metabolome of 82 plasma samples from patients with hepatocellular carcinoma (HCC; n = 51) and normal controls (n = 15), revealing that individual differences outweigh treatment differences.
View Article and Find Full Text PDFArticle Synopsis
- Intratumoral immune status plays a crucial role in how patients with intrahepatic cholangiocarcinoma respond to therapy, especially with a combination of gemcitabine, oxaliplatin, lenvatinib, and anti-PD1 antibody.
- High levels of certain CD8 T-cell markers (GZMB and proliferating CD8) and low levels of Macro CD5L predict better therapeutic responses, while shifts in T-cell markers indicate varying response levels.
- The study also suggests that using anti-CTLA4 antibody can counteract therapy resistance caused by immune exhaustion, paving the way for more effective cancer treatments based on immune profiling.
Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.
View Article and Find Full Text PDFImmune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
Emerg Microbes Infect
December 2023
Immune evasion by SARS-CoV-2 paired with immune imprinting from monovalent mRNA vaccines has resulted in attenuated neutralizing antibody responses against Omicron subvariants. In this study, we characterized two new XBB variants rising in circulation - EG.5.
View Article and Find Full Text PDFThe evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to challenge the efficacy of vaccination efforts against coronavirus disease 2019 (COVID-19). The Omicron XBB lineage of SARS-CoV-2 has presented dramatic evasion of neutralizing antibodies stimulated by mRNA vaccination and COVID-19 convalescence. XBB.
View Article and Find Full Text PDFEvolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.
View Article and Find Full Text PDFPurpose: We aimed to study the association between adjusted mtDNA levels in human trophectoderm biopsy samples and the developmental potential of euploid and mosaic blastocysts.
Methods: We analyzed relative mtDNA levels in 2,814 blastocysts obtained from 576 couples undergoing preimplantation genetic testing for aneuploidy from June 2018 to June 2021. All patients underwent in vitro fertilization in a single clinic; the study was blinded-mtDNA content was unknown at the time of single embryo transfer.
Hepatocellular carcinoma (HCC) is an aggressive malignancy with few effective treatment options. Lenvatinib is the first-line therapy for HCC but has only limited clinical benefit. Here, we explored the role and mechanism of the WD repeat domain 4 (WDR4) in lenvatinib resistance to improve clinical benefit.
View Article and Find Full Text PDFNew Omicron subvariants continue to emerge throughout the world. In particular, the XBB subvariant, which is a recombinant virus between BA.2.
View Article and Find Full Text PDFOmicron subvariants continuingly challenge current vaccination strategies. Here, we demonstrate nearly complete escape of the XBB.1.
View Article and Find Full Text PDFNewly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.
View Article and Find Full Text PDFThe rapid spread and strong immune evasion of the SARS-CoV-2 Omicron subvariants has raised serious concerns for the global COVID-19 pandemic. These new variants exhibit generally reduced fusogenicity and increased endosomal entry pathway utilization compared to the ancestral D614G variant, the underlying mechanisms of which remain elusive. Here, we show that the C-terminal S1 mutations of the BA.
View Article and Find Full Text PDFThe continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron subvariants, including BQ.1, BQ.1.
View Article and Find Full Text PDFThe rapid spread and strong immune evasion of the SARS-CoV-2 Omicron subvariants has raised serious concerns for the global COVID-19 pandemic. These new variants exhibit reduced fusogenicity and increased endosomal entry pathway utilization compared to the ancestral D614G variant, the underlying mechanisms of which remain elusive. Here we show that the C-terminal S1 mutations of the BA.
View Article and Find Full Text PDFContinued evolution of SARS-CoV-2 has led to the emergence of several new Omicron subvariants, including BQ.1, BQ. 1.
View Article and Find Full Text PDFEvasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant.
Cell Host Microbe
November 2022
The newly emerged BA.2.75 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant contains 9 additional mutations in its spike (S) protein compared to the ancestral BA.
View Article and Find Full Text PDF